Compare RYN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYN | IBRX |
|---|---|---|
| Founded | 1926 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.5B |
| IPO Year | 1994 | 2015 |
| Metric | RYN | IBRX |
|---|---|---|
| Price | $21.57 | $7.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $26.00 | $12.57 |
| AVG Volume (30 Days) | 2.1M | ★ 9.3M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.73% | N/A |
| EPS Growth | 26.78 | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $484,485,000.00 | $113,288,000.00 |
| Revenue This Year | $214.97 | $88.59 |
| Revenue Next Year | $10.35 | $131.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $19.49 | $1.95 |
| 52 Week High | $27.34 | $12.43 |
| Indicator | RYN | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 44.23 |
| Support Level | $20.98 | $6.69 |
| Resistance Level | $21.85 | $8.46 |
| Average True Range (ATR) | 0.56 | 0.42 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 38.93 | 38.59 |
Rayonier Inc is a timberland real estate investment trust engaged in the ownership, management, and investment of timberlands. The company operates through Southern Timber, Pacific Northwest Timber, and Real Estate segments. The Southern Timber and Pacific Northwest Timber segments are involved in harvesting timber and related activities, as well as value-added services such as licensing properties for hunting, leasing land for mineral extraction and communication infrastructure, land-based solutions including carbon capture and solar energy, and log trading. The Real Estate segment is engaged in land sales across various categories, as well as residential and commercial leasing activities. It generates the majority of its revenue from the Southern Timber segment.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.